The site offers API process development and manufacturing from preclinical to commercial manufacturing. The 74-acre campus includes 15 plants, including plants for HPAPI, flow chemistry and spray dried dispersion. The total reactor volume exceeds 1,800 m³.
It supports various API enabling technologies such as crystallization and particle engineering, biocatalysis, continuous manufacturing (flow chemistry), chemo-catalysis, and prep-HPLC & SFC & SMB.
Our Changzhou site has successfully passed numerous inspections by the US FDA, China NMPA, Japan PMDA, South Korea MFDS, and Brazil ANVISA.
